$VAR1 = undef;
Summary for peptidase M23.004: lysostaphin
| Names | |
|---|---|
| MEROPS Name | lysostaphin |
| Other names | lytU g.p. (Staphylococcus aureus) |
| Domain architecture |
|---|
| MEROPS Classification | |
|---|---|
| Classification | Clan MO >> Subclan (none) >> Family M23 >> Subfamily B >> M23.004 |
| Holotype | lysostaphin (Staphylococcus simulans), Uniprot accession P10547 (peptidase unit: 248-390), MERNUM MER0001419 |
| History | Identifier created: MEROPS 6.1 (10 January 2003) |
| Activity | |||
|---|---|---|---|
| Catalytic type | Metallo | ||
| Peplist | Included in the Peplist with identifier PL00235 | ||
| NC-IUBMB | Subclass 3.4 (Peptidases) >> Sub-subclass 3.4.24 (Metalloendopeptidases) >> Peptidase 3.4.24.75 | ||
| Enzymology | BRENDA database | ||
| Biotechnology | An agent for lysis of staphylococcal cell walls in the laboratory. | ||
| Pharmaceutical relevance | Lysostaphin is effective in treating experimental endophthalmitis mediated by methicillin-resistant Staphylococcus aureus (Dajcs et al., 2001; Dajcs et al., 2002). Its therapeutic value may be improved by conjugation with polyethylene glycol (Walsh et al., 2003). Lysostaphin cream eradicated Staphylococcus aureus nasal colonisation in a rat model (Kokai-Kun et al., 2003). | ||
